May 13, 2024 – Page 9 – Goldea Capital

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended March 31, 2024 and provided a business update. “Our entire clinical and preclinical development portfolio is progressing as planned,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Significantly, our Investigational New Drug (IND) application to the U.S. Food and Drug Administration for ART26.12, our lead Fatty Acid Binding Protein 5 (FABP5) inhibitor for the treatment of neuropathic pain, is in the final stages of preparation.” ART26.12...

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2% in the first quarter of 2023. AVISE® CTD trailing twelve-month average selling price (ASP) of $377, a 35.1% increase over the trailing twelve-month ASP in the first quarter of 2023. Net loss of $3.4 million in the first quarter of 2024, a 56.3% improvement over the first quarter of 2023. Adjusted EBITDA of $(2.0) million for the first quarter of 2024, a 67.7% improvement over the first...

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024

Written by Customer Service on May 13, 2024. Posted in Public Companies.

LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) — Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease. To register, click here. The event will focus on Abliva’s lead program, KL1333, which has shown clinically meaningful, early signals of efficacy in mitochondrial disease patients. This novel therapeutic approach modulates the underlying pathophysiology in mitochondrial disease. KL1333...

Husky Technologies™ Leverages ARHT Hologram Technology to Showcase Sustainable Solutions at the Premier Plastics Tradeshow in Orlando

Written by Customer Service on May 13, 2024. Posted in Public Companies.

TORONTO, May 13, 2024 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT” or “the Company”) (TSXV: ART), (OTCQB: ARHTF) the global leader in the development, production and distribution of high-quality, low latency hologram and digital content, is excited to announce that Husky TechnologiesTM (“Husky”), a renowned industry leader in sustainable packaging solutions and services, showcased their innovative “We Call You” capability as part of its proactive, predictive, and transparent monitoring solution, using ARHT CAPSULE at NPE 2024: The Plastics Show in Orlando from May 6-10. At the show, Husky’s Proactive Monitoring Specialist was represented by a lifelike AI Avatar developed by HOLOMEDIA AI, a global leader in quality content creation. This AI Avatar engaged attendees in an immersive and interactive...

LM Funding America, Inc. Schedules First Quarter 2024 Financial Results and Business Update Conference Call

Written by Customer Service on May 13, 2024. Posted in Public Companies.

TAMPA, FL, May 13, 2024 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a cryptocurrency mining and technology-based specialty finance company, today announced that it will host a conference call on Thursday, May 16, 2024, at 11:00 a.m. Eastern Time to discuss financial results for the quarter ended March 31, 2024, and provide a business update. The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 696741. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2917/50584 or on the investor relations section of the company’s website, https://www.lmfunding.com/investors/news-events/ir-calendar. A webcast replay will be...

Haveli Investments Completes Acquisition of ZeroFox

Written by Customer Service on May 13, 2024. Posted in Mergers And Acquisitions.

WASHINGTON, May 13, 2024 (GLOBE NEWSWIRE) — ZeroFox Holdings, Inc. (Nasdaq: ZFOX), a leading provider of external cybersecurity, today announced the completion of its acquisition by technology-focused private equity firm Haveli Investments. With the completion of the transaction, ZeroFox stockholders will receive $1.14 per share in cash. The Company’s common stock and warrants have ceased trading, and the Company has been delisted from Nasdaq. As a privately held company, ZeroFox will benefit from strategic support, guidance, and capital provided by Haveli Investments to continue expanding its global footprint in support of its mission to build a safer digital world. Through this investment, ZeroFox will continue to expand its industry leading cybersecurity platform, invest in go-to-new market channels, and accelerate innovation...

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD Subject was Safely Dosed with BB-301 in February- -Additional Interim Clinical Safety Data and Clinical Efficacy Data are Expected for Several Study Subjects in the Second Half of 2024- -23 OPMD Subjects have Enrolled into the OPMD Natural History Study with Multiple Subjects Eligible for Entry into the BB-301 Phase 1b/2a Clinical Treatment Study- –Closed an Oversubscribed Private Placement Financing of $40.0 Million on April 22nd, Cash Runway Extended Through 2025– HAYWARD, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology...

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in 2H24 Cash, cash equivalents and marketable securities of $241 million, expected to provide runway into 2026 FOSTER CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates. “We continue to execute our strategy and make important progress on our pipeline of potential best-in-class small molecule...

Cheetah Net Supply Chain Service Inc. Announces 1st Quarter 2024 Results and Provides Corporate Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

CHARLOTTE, N.C., May 13, 2024 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq CM: CTNT), a supplier of parallel-import vehicles sourced in the U.S. to be sold in the People’s Republic of China (the “PRC”) market, today reported results for the quarter ended March 31, 2024 and provided a corporate update. Recent Highlights Challenging market conditions in the PRC, first reported with respect to the Company’s financial performance during the second half of 2023, have continued into 2024. The Company’s financial results were impacted by these unfavorable market conditions in the first quarter of 2024, during which the Company experienced a significant decline in revenue. The gross margin between the U.S. retail prices of select luxury car models and their wholesale prices in the parallel-vehicle...

Alaska Energy Metals Advances Core Asset Focus With Sale of Mexico Subsidiary and Shareholding

Written by Customer Service on May 13, 2024. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) — Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) today announced: The sale of its shareholding in Felix Gold Ltd. (ASX: FXG) (“Felix Gold”), and The sale of its Mexico subsidiary, Recursos Millrock S. de R.L. de C.V. (“Recursos Millrock”). As a result of these sales, AEMC added non-dilutive capital to its balance sheet. “We have strategically re-built our asset portfolio to enhance our long-term sustainability and maintain focus on our Nikolai Nickel Project,” says Gregory Beischer, CEO of Alaska Energy Metals. “These sales allow us to realize value for these non-core assets. Alaska Energy Metals owns other gold property assets in Alaska that it may also consider selling.” Felix Gold SharesThe Company sold the Felix Gold shares...

Day: May 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice